Post

Moleculin doses first patients in Phase II portion of AML Annamycin combo study

Moleculin Biotech has dosed the first subjects in the Phase II portion of a Phase Ib/II trial evaluating the company’s …

Syndax leukaemia drug hits endpoint goals ahead of planned new drug application

Clinical-stage biopharmaceutical company, Syndax, has announced that it has met one of its goals as part of a Phase I/II …

Pipeline Moves: Advancement prospects plunge for myelodysplastic syndrome drug after trial termination

This week on Pipeline Moves, we kickoff by looking at the terminations of a Phase II trial in myelodysplastic syndrome …

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Novartis has announced positive interim results for iptacopan from the Phase III Applause-IgAN study showing significant proteinuria reduction in patients …

AbbVie’s venetoclax fails Phase III myeloma trial

AbbVie reported negative results from a Phase III CANOVA trial investigating venetoclax in patients with relapsed or refractory multiple myeloma. The …